|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide显示文摘Long-acting glucagon-like peptide-1(GLP-1) analogues marketed for type 2 diabetes(T2D) treatment have been showing positive and protective effects in several different tissues, including pancreas, heart or even brain. This gut secreted hormone plays a potent insulinotropic activity and an important role in maintaining glucose homeostasis. Furthermore, growing evidences suggest the occurrence of several commonalities between T2 D and neurodegenerative diseases, insulin resistance being pointed as a main cause for cognitive decline and increased risk to develop dementia. In this regard, it has also been suggested that stimulation of brain insulin signaling may have a protective role against cognitive deficits. As GLP-1 receptors(GLP-1R) are expressed throughout the central nervous system and GLP-1 may cross the blood-brain-barrier, an emerging hypothesis suggests that they may be promising therapeutic targets against brain dysfunctional insulin signaling-related pathologies. Importantly, GLP-1 actions depend not only on the direct effect mediated by its receptor activation, but also on the gut-brain axis involving an exchange of signals between both tissues via the vagal nerve, thereby regulating numerous physiological functions(e.g., energy homeostasis, glucose-dependent insulin secretion, as well as appetite and weight control). Amongst the incretin/GLP-1 mimetics class of anti-T2 D drugs with an increasingly described neuroprotective potential, the already marketed liraglutide emerged as a GLP-1R agonist highly resistant to dipeptidyl peptidase-4 degradation(thereby having an increased half-life) and whose systemic GLP-1R activity is comparable to that of native GLP-1. Importantly, several preclinical studies showed anti-apoptotic, anti-inflammatory, anti-oxidant and neuroprotective effects of liraglutide against T2 D, stroke and Alzheimer disease(AD), whereas several clinical trials, demonstrated some surprising benefits of liraglutide on weight loss, microglia inhibition, behavior and cognition, and in AD biomarkers. Herein, we discuss the GLP-1 action through the gut-brain axis, the hormone's regulation of some autonomic functions and liraglutide's neuroprotective potential. | Emanuel Monteiro Candeias Inês Carolina Sebastio Susana Maria Cardoso Sónia Catarina Correia Cristina Isabel Carvalho Ana Isabel Plácido Maria Sancha Santos Catarina Resende Oliveira Paula Isabel Moreira Ana Isabel Duarte | 2015 | World Journal of Diabetes2015，6，6： | 9 |
| 2 | Animal models for therapeutic embolization显示文摘 | Moreira PL An YH | 2003 | Cardiovasc Interven Radiol2003，26，4： | 1 |
| 3 | In vitro analysis of anionic collagen scaffolds for bone repair显示文摘 | Moreira PL An YH Santos AR Jr | 2004 | J Biomed Mater Res2004，1571，2： | 1 |
| 4 | Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts 显示文摘 | Moreira PI Harris PL Zhu X | 2007 | J Alzheimers Dis2007，12，2： | 1 |
| 5 | Association between oxidative stress and nutritional status in the elderly显示文摘 | Moreira PL Villas Boas PJ Ferreira AL | 2014 | Rev Assoc Med Bras2014，60，1： | 1 |
| 6 | Animal models for therapeutic embolization 显示文摘 | Moreira PL An YH | 2003 | Cardiovase Intervent Radiol2003，26，2： | 1 |
| 7 | Compensatory responses induced by oxidative stress in Alzheimer disease显示文摘 | Moreira PI Zhu X Liu Q Honda K Siedlak SL Harris PL | 2006 | Biol Res2006，39，1： | 1 |
| 8 | Association between oxidative stress and nutritional status in the elderly显示文摘 | Moreira PL Villas Boas PJ Ferreira AL | 2014 | Rev Assoc Med Bras2014，60，1： | 1 |
| 9 | Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts显示文摘 | Moreira PI Harris PL Zhu X | 2007 | J Alzheimers Dis2007，12，2： | 1 |
| 10 | Increasing pancreatic cancer is not paralleled by pancreaticoduodenectomy volumes in Brazil:A time trend analysis显示文摘Background: Currently, surgical resection represents the only curative treatment for pancreatic cancer(PC), however, the majority of tumors are no longer resectable by the time of diagnosis. The aim of this study was to describe time trends and distribution of pancreaticoduodenectomies(PDs) performed for treating PC in Brazil in recent years. Methods: Data were retrospectively obtained from Brazilian Health Public System(namely DATASUS) regarding hospitalizations for PC and PD in Brazil from January 2008 to December 2015. PC and PD rates and their mortalities were estimated from DATASUS hospitalizations and analyzed for age, gender and demographic characteristics. Results: A total of 2364 PDs were retrieved. Albeit PC incidence more than doubled, the number of PDs increased only 37%. Most PDs were performed in men(52.2%) and patients between 50 and 69 years old(59.5%). Patients not surgically treated and those 70 years or older had the highest in-hospital mortality rates. The most developed regions(Southeast and South) as well as large metropolitan integrated municipalities registered 76.2% and 54.8% of the procedures, respectively. LMIM PD mortality fluctuated, ranging from 13.6% in 2008 to 11.8% in 2015. Conclusions: This study suggests a trend towards regionalization and volume-outcome relationships for PD due to PC, as large metropolitan integrated municipalities registered most of the PDs and more stable mortality rates. The substantial differences between PD and PC increasing rates reveals a limiting step on the health system resoluteness. Reduction in the number of hospital beds and late access to hospitalization, despite improvement in diagnostic methods, could at least in part explain these findings. | Lucila M Perrotta de Souza Jessica PL Moreira Homero S Fogaca José Marcus Raso Eulálio Ronir R Luiz Heitor SP de Souza | 2019 | Hepatobiliary & Pancreatic Diseases International2019，18，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员